AIDS-associated lymphoma

  • Matthew D. Volm
  • Jamie H. Von Roenn
Part of the Cancer Treatment and Research book series (CTAR, volume 99)


In 1982, the first report of aggressive B-cell non-Hodgkin’s lymphoma (NHL) occurring in homosexual men was published in the medical literature [1]. Three years later, the Center for Disease Control (CDC) added NHL to its list of acquired immune deficiency syndrome (AIDS)-defining illnesses in persons infected with the human immunodeficiency virus (HIV). Today, NHL remains a formidable challenge for physicians caring for HIV-infected persons.


Human Immunodeficiency Virus Human Immunodeficiency Virus Infection Acquire Immune Deficiency Syndrome Primary Central Nervous System Lymphoma Diffuse Large Cell Lymphoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ziegler JL, Drew WL, Miner RC, et al. 1982. Outbreak of Burkitt’s-like lymphoma in homosexual men. Lancet 2:631–633.PubMedCrossRefGoogle Scholar
  2. 2.
    Beral V, Peterman T, Berkelman R, Jaffe H. 1993. AIDS-associated non-Hodgkin’s lymphoma. Lancet 337:805–809.CrossRefGoogle Scholar
  3. 3.
    Serriano D, Salamina G, Franceschi S, Dubois D, La Vecchia C, Brunei JB, Ancelle-Park RA. 1992. The epidemiology of AIDS-associated non-Hodgkin’s lymphoma in the World Health Organization European region. Br J Cancer 66:912–916.Google Scholar
  4. 4.
    Rabkin CS, Hilgartner MW, Hedberg KW, Aledort LM, Hatzakis CM, Lederman MM, de Moerloose P, Bray GL, Cohen AR, Andes A, Manco-Johnson M, Schramm W, Kroner BL, Blattner WA, Goedert JJ. 1992. Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA 267:1090–1094.PubMedCrossRefGoogle Scholar
  5. 5.
    Ragni MV, Belle SH, Jaffe RA, Duerstein SL, Bass DC, McMillan CW, Lovrien EW, Aledort LM, Kisker CT, Stabler SP, Hoots WK, Hilgartner MW, Cos-Gill J, Buchanan GR, Sanders NL, Brettler DB, Barron LE, Goldsmith JC, Ewenstein B, Smith KJ, Green D, Addiego JE, Kingsley LA. 1993. Acquired Immunodeficiency Syndrome-associated non-Hodgkin’s lymphomas and other malignancies in patients with hemophilia. Blood 81:1889–1897.PubMedGoogle Scholar
  6. 6.
    Lyter DW, Kingsley LA, Rinaldo CR, Bryant J. 1996. Malignancies in the Multicenter AIDS Cohort Study (abstract). Proc Am Soc Clin Oncol 15:305.Google Scholar
  7. 7.
    Munoz A, Schrager LK, Bacellar H, Speizer I, Vermund SH, Detels R, Shah AJ, Kingsley LA, Seminara D, Phair JP. 1993. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the multicenter AIDS cohort study: 1985–1991. Am J Epidemiol 137:423–428.PubMedGoogle Scholar
  8. 8.
    Pluda JM, Venzon DJ, Tosato G, lietzau J, Wyvill K, Nelson DL, Jaffe ES, Karp JE, Broder S, Yarchoan R. 1993. Parameters affecting the development of non-Hodgkin’s lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 11:1099–1107.PubMedGoogle Scholar
  9. 9.
    Roithmann S, Tourani JM, Andrieu JM. 1991. AIDS-associated non-Hodgkin’s lymphoma (letter). Lancet 338:884–885.PubMedCrossRefGoogle Scholar
  10. 10.
    Boyle MJ, Swanson CE, Turner JJ. 1990. Definition of two distinct types of AIDS-associated non-Hodgkin lymphoma. Br J Haematol 76:496–512.Google Scholar
  11. 11.
    Pederson C, Gerstoft J, Lundgren JD, Skinhoj P, Bottzauw J, Geisler C, Hamilton-Dutoit SJ, Thorsen S, Lisse I, Ralfkiaer E, Pallesen G. 1991. HIV-associated lymphoma: histopathology and association with Epstein-Barr virus genome related to clinical, immunological and prognostic features. Eur J Cancer 27:1416–1423.Google Scholar
  12. 12.
    Pluda JM, Yarchoan R, Jaffe ES, Feuerstein IM, Soloman D, Steinberg SM, Wyvill KM, Raubitschek A, Katz D, Broder S. 1990. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term anti-retroviral therapy. Ann Intern Med 113:276–282.PubMedGoogle Scholar
  13. 13.
    Moore RD, Kessler H, Richman DD, Flexner C, Chaisson RE. 1991. Non-Hodgkin’s lymphoma in patients with advanced HIV infection treated with zidovudine. JAMA 265:2208–2211.PubMedCrossRefGoogle Scholar
  14. 14.
    Levine AM, Bernstein L, Sullivan-Halley J, Shibata D, Mahterian SB, Nathwani BN. 1995. Role of zidovudine in anti-retroviral therapy in the pathogenesis of acquired immunodeficiency syndrome-related lymphoma. Blood 86(12):4612–4616.PubMedGoogle Scholar
  15. 15.
    Knowles DM, Chamaluk GA, Subar M, Burke JS, Dugan M, Wernz J, Slywotzky C, Pelicci PG, Dalla-Favera R, Raphael B. 1988. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 108:744–753.PubMedGoogle Scholar
  16. 16.
    Kaplan LD, Abrams DI, Feigel E, McGrath M, Kahn J, Neville P, Ziegler J, Volberding PA. 1989. AIDS-associated non-Hodgkin’s lymphoma in San Francisco. JAMA 261:719–724.PubMedCrossRefGoogle Scholar
  17. 17.
    Iochim HL, Dorsett B, Cronin W, Maya M, Wahl S. 1991. Acquired immunodeficiency syndrome-associated lymphomas: clinical, pathologic and viral characteristic of 111 cases. Hum Pathol 22659–22673.Google Scholar
  18. 18.
    Raphael MM, Gentilhomme O, Tulliez M, Byron PA, Diebold J. 1991. Histopathologic features of high-grade non-Hodgkin’s lymphomas in acquired immunodeficiency syndrome. Arch Pathol Lab Med 115:15–20.PubMedGoogle Scholar
  19. 19.
    Dorfman RF, Burke JS, Berard CW. 1982. A working formulation for non-Hodgkin’s lymphomas: background, recommendations, histological criteria and relationship to other classifications. In: Rosenberg S, Kaplan HS (eds), Malignant Lymphomas. Aademic Press: New York.Google Scholar
  20. 20.
    Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary M, Delsol G, Wolf-Peters C, Falini, Gatter KC, Grogan T, Isaacson PC, Knowles DM, Mason DY, Muller-Hermelink HK, Pileri SA, Piris MA, Ralfkier E, Warmke RA. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392, 1994.PubMedGoogle Scholar
  21. 21.
    Penn I. 1991. Cancer in the immunosuppressed organ recipient. Transplant Proc 23:1771–1772.PubMedGoogle Scholar
  22. 22.
    Penn I. 1981. Depressed immunity and the development of cancer. Clin Exp Immunol 46:459–474.PubMedGoogle Scholar
  23. 23.
    Hanto DW, Sakamoto K, Purtilo DT, Simmons RI, Najarian JS. 1981. The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Surgery 90:204.PubMedGoogle Scholar
  24. 24.
    Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA, Michler RE. 1995. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85:552–565.PubMedGoogle Scholar
  25. 25.
    Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW Jr, Hardesty RL, Atchinson RW, Jaffe R, Bahnson HT. 1984. Reversibility of lymphomas and lymphoproliferative lesion developing under cyclosporin-steroid therapy. Lancet (8377):583–587.Google Scholar
  26. 26.
    Hanto DW, Frizzera G, Purtilo DT, Sakamoto K, Sullivan JL, Saemundsen AK, Klein G, Simmons RL, Najarian JS. 1981. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 41:4253–4261.PubMedGoogle Scholar
  27. 27.
    Shiramizu B, Hernadier B, Meeker T, Kaplan L, McGrath M. 1992. Molecular and immunophenotypic characterization of AIDS-associated Epstein-Barr virus negative, polyclonal lymphoma. J Clin Oncol 10:383.PubMedGoogle Scholar
  28. 28.
    Ballerini P, Gaidano G, Gong JZ, Tassi, Saglio G, Knowles DM, Dalla-Favera R. 1993. Multiple genetic in acquired immunodeficiency syndrome-related hon-Hodgkin’s lymphoma. Blood 81:166–176.PubMedGoogle Scholar
  29. 29.
    Shibata D, Weiss LM, Hernandez AM, Nathwani BN, Bernstein L, Levine AM. 1993. Epstein-Barr virus-associated non-Hodgkin’s lymphoma in patients infected with the human immunodeficiency virus. Blood 81:2102–2109.PubMedGoogle Scholar
  30. 30.
    Shiramizu B, Herndier B, Meeker T, Kaplan L, McGrath M. 1992. Molecular and immunophenotypic characterization of AIDS-associated, Epstein-Barr virus-negative, polyclonal lymphoma. J Clin Oncol 10:383–389.PubMedGoogle Scholar
  31. 31.
    Hernadier BG, Kaplan LD, McGrath M. 1994. Pathogenesis of AIDS lymphomas. AIDS 8:1025–1049.CrossRefGoogle Scholar
  32. 32.
    List AF, Greco FA, Vogler LB. 1987. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol 5:1673–1689.PubMedGoogle Scholar
  33. 33.
    Pegano JC, Huang MS, Levine P. 1973. Absence of Epstein-Barr virus in American Burkitt’s lymphoma. N Engl J Med 289:1395–1399.CrossRefGoogle Scholar
  34. 34.
    Whittle HC, Brown J, Marsh K, et al. 1994. T cell control of Epstein-Barr virus is lost during P. falciparum malaria. Nature 312:449–450.CrossRefGoogle Scholar
  35. 35.
    Shibata D, Weiss LM, Nathwani BN, Brynes RK, Levine AM. 1991. Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin’s lymphoma. Blood 77:1527–1533.PubMedGoogle Scholar
  36. 36.
    Bashir RM, Harris NL, Hochberg FH, Singer RM. 1989. Detection of Epstein-Barr virus in CNS lymphomas by in-situ hybridization. Neurology 39:813–817.PubMedGoogle Scholar
  37. 37.
    MacMahon EME, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, MacArthur JC, Ambinder RF. 1991. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338:969–973.PubMedCrossRefGoogle Scholar
  38. 38.
    Camilleri-Broet S, Davi F, Feuillard J, Bourgeois C, Seilhean D, Hauw JJ, Raphael M. High expression of latent membrane protein 1 of Epstein-Barr virus and Bcl-2 oncoprotein in acquired immunodeficiency-related primary brain lymphomas. Blood 86(2):432–435, 1995.PubMedGoogle Scholar
  39. 39.
    Laurence J, Astrin SM. 1991. Human immunodeficiency virus induction of malignant transformation in human B lymphocytes. Proc Natl Acad Sci 88:7635–7639.PubMedCrossRefGoogle Scholar
  40. 40.
    Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposi’s sarcoma-associated herpesvirus-like DNA in AIDS-related body cavity-based lymphomas. N Engl J Med 352:1186–1191.CrossRefGoogle Scholar
  41. 41.
    Chang Y, Cesarman E, Pessin MS, et al. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science 266:1865–1869.PubMedCrossRefGoogle Scholar
  42. 42.
    Panteloleo G, Graziosi C, Butini L, et al. 1991. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci USA 88:9838–9842.CrossRefGoogle Scholar
  43. 43.
    Martinez-Maza O, Crabb E, Mitsuyasu RT, Fahey JL, Giorgi JV. 1988. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol 138:3720.Google Scholar
  44. 44.
    Lane H, Masur H, Edgar K, Whalen G, Rook A, Fauci A. 1986. Abnormalities of B-cell activation and immunodeficiency virus. J Clin Microbiol 25:364–369.Google Scholar
  45. 45.
    Schnittman S, Lane H, Higgins S, Folks T, Fauci A. 1986. Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science 233:1084–1086.PubMedCrossRefGoogle Scholar
  46. 46.
    Monroe JG, Silberstein LE. 1995. HIV-mediated B-lymphocyte activation and lymphomagenesis. J Clin Immunol 15:61–68.PubMedCrossRefGoogle Scholar
  47. 47.
    Berberian L, Goodglick L, Kipps T, Braun J. 1993. Immunoglobulin VH3 gene products: natural ligands for HIV gpl20. Science 261:1588–1591. Vol 261.PubMedCrossRefGoogle Scholar
  48. 48.
    Chirmule N, Kalyanaraman VS, Lederman S, Oyaizu N, Yagura H, Yellin MJ, Chess L, Pahwa S. 1993. HIV-gp 160-induced T-cell dependent B cell differentiation. J Immunol 150:2478–2486.PubMedGoogle Scholar
  49. 49.
    Boue F, Wallon C, Goujard C, Barre-Sinoussi F, Galanaud P, Delfraissy JF. 1992. HIV induces IL-6 production by human B lymphocytes. J Immunol 148:3761–3767.PubMedGoogle Scholar
  50. 50.
    Silvestris F, Williams RC, Dammacco F. 1995. Autoreactivity in HIV-1 infection: the role of molecular mimicry. Clin Immunol Immunopathol 75:197–205.PubMedCrossRefGoogle Scholar
  51. 51.
    Nicholson JKA, McDougal JS, Spiro TJ, Cross GD, Jones BM, Reinberg EL. 1984. Immunoregulatory subsets of the T helper and T suppressor population in homosexual men with chronic, unexplained lymphadenopathy. J Clin Invest 73:191–201.PubMedGoogle Scholar
  52. 52.
    Karp JE, Broder S. 1991. Acquired immunodeficiency syndrome and non-Hodgkin’s lym-phomas. Cancer Res 51:4743–4756.PubMedGoogle Scholar
  53. 53.
    Levine AM. 1992. Acquired immunodeficiency related lymphoma. Blood 80:8–20.PubMedGoogle Scholar
  54. 54.
    Birx DL, Redfield RR, Tencer K, Fowler A, Burke DS, Tosato G. 1990. Induction of interleukin 6 during human immunodeficiency virus infection. Blood 76:2303-••.PubMedGoogle Scholar
  55. 55.
    Emilie D, Peuchmaur M, Maillot MC, Crevon MC, Broussse N, Delfraissy JF, Dormont J, Galanaud P. 1990. Production of interleukins in human immunodeficiency virus —1-replicating lymph nodes. J Clin Invest 86:148.PubMedCrossRefGoogle Scholar
  56. 56.
    Amadori A, Zamarchi R, Veronese ML, Panozzo M, Barelli A, Borri A, Colotta F, Mantovani A, Chieco-Bianchi L. 1991. B cell activation during HIV-1 infection: cell to cell interactions and cytokine requirements. J Immunol 146:57.PubMedGoogle Scholar
  57. 57.
    Pluda JM, Venzon D, Tosato G, Lietzau, Shay LE, Karp JE, Broder S, Yarchoan R. 1993. Parameters affecting the development of non-Hodgkin’s lymphomas in patients with HIV infection receiving anti-retroviral therapy. Journal of Clinical Oncology 11:1099–1107.PubMedGoogle Scholar
  58. 58.
    Emilie D, Coumbras MR, Devergne O, Delecluse HJ, Gisselbrecht C, Michiels JF, Van Damme J, Taga T, Kishimoto T, Crevon MC, Galanaud P. 1992. Interleukin-6 production in high-grade B lymphomas: correlation with presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus-sero-negative patients. Blood 80:498–504.PubMedGoogle Scholar
  59. 59.
    Levine AM, Tulpule A, Espina B, et al. 1994. Low-dose M-BACOD with zalcitabine (ddC) in patients with AIDS lymphoma (NHL): correlation between serum IL-6, systemic ‘B’ symptoms, viral burden and response to therapy. Blood 84(10, Suppl l):519a.Google Scholar
  60. 60.
    Delecluse HJ, Raphael M, Magaud JP, Felman P, Abd Alsamad I, Bornkamm GW, Lenoir GM. 1993. Variable morphology of human immunodeficiency virus-associated lymphomas with c-myc rearrangements. Blood 82:552–563.PubMedGoogle Scholar
  61. 61.
    Subar M, Neri A, Inghirami G, Knowles DM, Dalla-Favera R. 1988. Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood 72:667–671.PubMedGoogle Scholar
  62. 62.
    Dalla-Favera R, Ye BH, Cattoretti G, LoCoco F, Chang CC, Zhang J, Migliazza A, Cechova K, Chaganti S, Chen W, Louie DC, Offit K, Chaganti RSK. 1996. BCL-6 in diffuse large cell-lymphomas. In: De Vita V et al. (eds), Important Advances in Oncology 1996. Lippincott-Raven: Philadelphia.Google Scholar
  63. 63.
    Gaidano G, LoCoco F, Ye B, Shibata D, Levine AM, Knowles DM, Dalla-Favera. 1994. Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma: association with diffuse large cell subtype. Blood 84:397–402.PubMedGoogle Scholar
  64. 64.
    Levine AM, Sullivan-Halley K, Pike MC, Rarick MU, Loureiro C, Bernstein-Singer M, Wilson E, Brynes R, Parker J, Rasheed S, Gill PS. 1991. HIV-related lymphoma: prognostic factors related to survival. Cancer 68:2466.PubMedCrossRefGoogle Scholar
  65. 65.
    Sider L, Weiss AJ, Smith MD, Von Roenn JH, Glassroth J. 1989. Varied appearance of AIDS-related lymphoma in the chest. Radiology 171:629–632.PubMedGoogle Scholar
  66. 66.
    Shipp MA et al., for the International Non-Hodgkin’s Lymphoma Prognostic Factors Project. 1993. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329:987–994.CrossRefGoogle Scholar
  67. 67.
    Vaccher E, Spina M, Errante D, Tavio M, Nasti G, Simonelli C, Talamini R, Tirelli U. 1996. Age and LDH are independent prognostic factors also in HIV-related non-Hodgkin’s lymphoma: a monoinstitutional study of 96 patients. Proc Am Soc Clin Oncol 15:304a.Google Scholar
  68. 68.
    Kaplan LD, Abrams DI, Feigal E, McGrath M, Kahn J, Neville P, Ziegler J, Volberding. 1989. AIDS-associated non-Hodgkin’s lymphoma in San Francisco. JAMA 261:719–724.PubMedCrossRefGoogle Scholar
  69. 69.
    Pederson C, Gerstoft J, Lundgren JD, Skinhoj P, Bottzauw J, Geisler C, Hamilton-Dutiot SJ, Thorsen S, Lisse, Ralfkier E, Pallesen. 1991. HIV-associated lymphoma: histopathology and association with Epstein-Barr virus genome related clinical, immunological and prognostic features. European Journal of Cancer 27:1416–1423.CrossRefGoogle Scholar
  70. 70.
    Formenti SC, Gill PS, Lean E, Rarick M, Meyer PR, Boswell W, Petrovich Z, Chak L, Levine AM. 1989. Primary central nervous system lymphoma in AIDS: results of radiation therapy. Cancer 63:1101–1107.PubMedCrossRefGoogle Scholar
  71. 71.
    Goldstein JD, Dickson DW, Moser FG, Hirschfield AD, Freeman K, Llena JF, Kaplan B, Davis L. 1991. Primary central nervous system lymphoma in acquired immune deficiency syndrome: a clinical and pathologic study with results of treatment with radiation. Cancer 67:2756–2765.PubMedCrossRefGoogle Scholar
  72. 72.
    Baumgartner JE, Rachlin JR, Beckstead JH, Meeker TC, Levy RM, Wara WM, Rosenblum ML. 1990. Primary central nervous lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 73:206–211.PubMedGoogle Scholar
  73. 73.
    Levine AM, Wernz JC, Kaplan L, Rodman N, Cohen P, Metroka C, Bennett JM, Rarick MU, Walsh C, Kahn J, Miles S, Ehman C, Feinberg, Nathwani B, Gill PS, Mitsuyasu R. 1991. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma: a prospective multi-institutional trial. JAMA 266:84–88.PubMedCrossRefGoogle Scholar
  74. 74.
    Gordon LI, Harrington D, Andersen J, Colgon J, Glick J, Neimon R, Mann R, Resniek GD, Barcos M, Galtlieb A, O’Connell M. 1992. Comparison of a second generation combination chemotherapy regimen (M-BACOD) with a standard regimen (CHOP) for advanced diffuse non-hodgkins lymphoma. New England Journal of Medicine 327:1342–1349.PubMedCrossRefGoogle Scholar
  75. 75.
    Fisher RI, Gayrot ER, Dahlberg S et al. 1997. Comparison of standard regimen (CHOP) with three impasive chemotherapy regimens for advanced non-hodgkins lymphoma. New England Journal of Medicine 328:1002–1006.CrossRefGoogle Scholar
  76. 76.
    Gill PS, Levine AM, Krailo M, Rarick MU, Loureiro C, Deyton L, Meyer P, Rasheed S. 1987. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol 5:1322–1328.PubMedGoogle Scholar
  77. 77.
    Tirelli U, Errante E, Oskenhendler E, Spina M, Vaccher E, Serraino D, Gastaldi R, Repetto L, Rizzardini G, Carbone A, Bertola G, Mandelli F, Monfardini S, Gisselbrecht C. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor prognosis AIDS-related non-Hodgkin’s lymphoma.Google Scholar
  78. 78.
    Gisselbrecht C, Oskenhendler E, Tirelli U, Lepage E, Gabarre J, Farcet JP, Gastaldi R, Coiffier B, Thyss A, Raphael M, Monfardini S. 1993. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. Am J Med 95:188–196.PubMedCrossRefGoogle Scholar
  79. 79.
    Kaplan L, Straus D, Levine AM. 1995. Randomized trial of standard dose m-BACD with GM-CSF vs. reduced dose m-BACOD for systemic HIV associated lymphoma: ACTG 142. Proc Am Soc Clin Oncol 14:288a.Google Scholar
  80. 80.
    Sawka C, Shepherd F, Brandwein J, Berinstein N, Singer J. 1994. Novel combination chemotherapy for HIV-related non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 13:53a.Google Scholar
  81. 81.
    Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams DI, Tracy J, Volberding PA. 1991. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma: results of a randomized trial. J Clin Oncol 9:929–940.PubMedGoogle Scholar
  82. 82.
    Sparano JA, Wiernik PH, Leaf A, Henry D, Mason B, Sarta C, Hu X, Dutcher JP. 1995. Didanosine (ddI) ameliorates neutropenia in patients with HIV-related non-Hodgkin’s lymphoma (NHL) treated with infusional cyclophosphamide, doxorubicin and etoposide (CDE). Proc Annu Meet Am Assoc Cancer Res 36:1207a.Google Scholar
  83. 83.
    Levine AM, Katz-Wilson E, Espina B, et al. 1992. Low dose m-BACOD and concomitant dideoxycytidine (ddC) in AIDS-related lymphoma: Blood 80:328a.Google Scholar
  84. 84.
    Ucar A, Harrington WJ, Cabrai L, Hurley J, Cohen J, Lai S, Byrnes J. 1994. Phase II trial of chemotherapy concomitantly with DDI versus chemotherapy alone in patients with AIDS-non-Hodgkin’s lymphoma. Proc Annu Meet Am Soc Clin Oncol 13:1265a.Google Scholar
  85. 85.
    Errante D, Gastaldi R, Nigra E, Nosari AM, Magnani G, Vaccher E, Bernardi D, Tirelli U. 1995. VP-16, mitoxantrone and prednimustine(VMP): an effective palliative chemotherapy regimen in patients with relapsed HIV-related non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 14:290a.Google Scholar
  86. 86.
    Levine AM, Weiss GR, Tupule F, Kaplan L, Giles F, Luskey BD, Scadden DT, Pearce T, Silverberg I, Busqueis A, von Hoff DD. 1995. Multi-center phase II study of mitoguazone (MGBG) in relapsed or refractory AIDS-lymphoma. Proc Am Soc Clin Oncol 14:288.Google Scholar
  87. 87.
    Sparano JA, Wiernik PH, Dutcher JP, Sarta C, Strack M, Leaf A. 1996. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin’s lymphoma: a follow-up report of a highly active regimen. Blood 86(Suppl 1):386a.Google Scholar
  88. 88.
    Sparano JA, Wiernik PH, Strack M, Leaf A, Becker N, Valentine ES. 1993. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus and human T cell leukemia virus type a-related non-Hodgkin’s lymphoma: a highly active regimen. Blood 81:2810–2815.PubMedGoogle Scholar
  89. 89.
    Tulpule A, Anderson LJJ, Levine AM, Espina B, Esplin J, Boswell W, Scadden D, Esseltine D, Epstein CL. 1994. Anti-B4 (CD19) monoclonal antibody, conjugated with ricin (B4-blocked ricin: B4BR) in refractory AIDS lymphoma. Proc Am Soc Clin Oncol 13:52a.Google Scholar
  90. 90.
    Emilie D, Wijdenes J, Gisselbrecht C, Jarrousse B, Billaud B, Blay JY, Gabarre J, Gaillard JP, Brochier J, Raphael M, Boue F, Galanaud P. 1994. Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on clinical B symptoms. Blood 84:2472–2479.PubMedGoogle Scholar
  91. 91.
    Bernstein ZP, Porter MM, Gould M, Lipman B, Bluman EM, Stewart CC, Hewitt RG, Fyfe G, Caligiuri MA. 1995. Prolonged administration of low dose interleukin 2 in human immunodeficiency virus associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 86:3287–3294.PubMedGoogle Scholar
  92. 92.
    Grillo-Lopez AJ, Maloney DG, Bodkinu D, Schilder RI, White C, Foon K, Janakiraman N, Neidhart J, Rosenberg J, Shen CD, et al. IDEC-C2B8: initial phase II results in patients with B-cell lymphoma (Meeting abstract). 9th Annual Scientific Meeting of the Society for Biological Therapy: Biological Therapy of Cancer IX, October, 1994.Google Scholar
  93. 93.
    Khatri VP, Baiocchi RA, Bernstein ZP, Caligiuri MA. 1997. Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer. Cancer Journal From Scientific American 3:S129–S136.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Matthew D. Volm
  • Jamie H. Von Roenn

There are no affiliations available

Personalised recommendations